Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology
Minoru FukudaNagasaki Thoracic Oncology Group

Abstract

Irinotecan, a topoisomerase I inhibitor, is an effective agent for non-small-cell lung cancer (NSCLC). To determine the efficacy and toxicity of irinotecan and carboplatin, we conducted a phase II study in 61 patients with advanced NSCLC. Every 4 weeks, the patients received irinotecan 50 mg/m2 (days 1, 8 and 15) and carboplatin (day 1) with a target AUC of 5 mg min/ml using the Chatelut formula. All patients were evaluable for toxicity, and of 59 patients evaluable for response, 20 achieved a partial response and 26 showed no change. The overall response rate was 34% (95% confidence interval 23-48%). Grade 3 or 4 anemia, leukopenia, neutropenia, thrombocytopenia and diarrhea occurred in 32%, 32%, 60%, 25%, and 7%, respectively. The median survival time and 1-year, and 2-year survival rates were 10.0 months, 37.6%, and 15.2%, respectively. Irinotecan with carboplatin is effective for advanced NSCLC and safe.

References

Nov 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A H CalvertE Wiltshaw
Sep 1, 1985·Cancer Treatment Reviews·W C Rose, J E Schurig
Apr 19, 1995·Journal of the National Cancer Institute·E ChatelutR Bugat
Sep 1, 1996·Critical Reviews in Oncology/hematology·N MasudaM Fukuoka
Jun 1, 1997·Chest·C F Mountain, C M Dresler
Oct 7, 1997·Clinical Pharmacokinetics·S B Duffull, B A Robinson
May 30, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Lokich, N Anderson
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F DeVoreL L Miller
Jul 4, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M OkaS Kohno
Jan 11, 2002·The New England Journal of Medicine·Kazumasa NodaUNKNOWN Japan Clinical Oncology Group
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Oct 12, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M OkaS Kohno
Nov 26, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Koji TakedaShunichi Negoro
Feb 6, 2003·British Journal of Cancer·S NegoroUNKNOWN CPT-11 Lung Cancer Study Group West
Mar 1, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Filippo De MarinisUNKNOWN Foundation for Oncological Research
Jun 27, 2003·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yoshihiko SegawaUNKNOWN Okayama Lung Cancer Study Group
Jan 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin J EdelmanDavid R Gandara
Jul 6, 2004·International Journal of Radiation Oncology, Biology, Physics·Steven E SchildJames R Jett
Aug 25, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katsuyuki HottaMitsune Tanimoto
Jun 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harvey B NiellUNKNOWN Cancer and Leukemia Group

❮ Previous
Next ❯

Citations

Feb 18, 2009·Cancer Chemotherapy and Pharmacology·Myung Hee ChangKeunchil Park
Feb 11, 2016·Asia-Pacific Journal of Clinical Oncology·Masashi TakanoYuh Sakata
Jan 2, 2008·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Nicholas W ChoongAnn M Mauer
Apr 22, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chia-Hsuin ChangK Arnold Chan
Jun 10, 2011·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Minh-Tâm BaylatryAlex Laurent
Aug 23, 2005·Cancer Chemotherapy and Biological Response Modifiers·Max KreditorHoward S Hochster
Jun 7, 2005·Expert Opinion on Therapeutic Targets·Ladislav Novotny, Thomas Szekeres
Apr 20, 2006·British Journal of Cancer·A KinoshitaUNKNOWN Nagasaki Thoracic Oncology Group (NTOG)
Dec 6, 2014·Hospital Pharmacy·Matthew R RutledgeDominic A Solimando

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.